Business Description
SAB Biotherapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US78397T2024
Total Employee Number:
86Description
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.4 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 2.14 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 33.6 | |||||
3-Year FCF Growth Rate | 49.8 | |||||
3-Year Book Growth Rate | -19.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.83 | |||||
9-Day RSI | 58.43 | |||||
14-Day RSI | 55.8 | |||||
3-1 Month Momentum % | 2.09 | |||||
6-1 Month Momentum % | 1.56 | |||||
12-1 Month Momentum % | 114.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.45 | |||||
Quick Ratio | 11.45 | |||||
Cash Ratio | 10.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -111.4 | |||||
Shareholder Yield % | -29.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -0.35 | |||||
ROA % | -0.3 | |||||
ROIC % | -89.46 | |||||
3-Year ROIIC % | -48.82 | |||||
ROC (Joel Greenblatt) % | -0.81 | |||||
ROCE % | -0.13 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.24 | |||||
EV-to-EBIT | -1121.91 | |||||
EV-to-Forward-EBIT | -2.28 | |||||
EV-to-EBITDA | 63.62 | |||||
EV-to-Forward-Revenue | 11.37 | |||||
EV-to-FCF | -3.52 | |||||
| Price-to-Net-Current-Asset-Value | 3.07 | |||||
| Price-to-Net-Cash | 3.26 | |||||
Earnings Yield (Greenblatt) % | -0.09 | |||||
FCF Yield % | -18.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SABS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SAB Biotherapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.306 | ||
| Beta | -0.8305 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 69.38 | ||
| 14-Day RSI | 55.8 | ||
| 14-Day ATR ($) | 0.245753 | ||
| 20-Day SMA ($) | 3.6005 | ||
| 12-1 Month Momentum % | 114.29 | ||
| 52-Week Range ($) | 1.67 - 6.6 | ||
| Shares Outstanding (Mil) | 76.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SAB Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SAB Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 140 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 42 days | ||
| General meeting for 2026 | 2026-06-18 10:00 | 3.86 (+3.76%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:30 | 3.72 (-11.43%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.72 (-11.43%) | ||
| Barclays 28(th) Annual Global Healthcare Conference | 2026-03-11 08:30 | 4.10 (+1.23%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 15:00 | 3.79 (+2.16%) | ||
| Annual report for 2025 | 2026-03-09 | 3.79 (+2.16%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 3.79 (+2.16%) | ||
| Oppenheimer 36(th) Annual Healthcare Life Sciences Conference | 2026-02-25 08:40 | 3.74 (+2.19%) |
Show
Entries
SAB Biotherapeutics Inc Frequently Asked Questions
What is SAB Biotherapeutics Inc(SABS)'s stock price today?
The current price of SABS is $3.73. The 52 week high of SABS is $6.60 and 52 week low is $1.67.
When is next earnings date of SAB Biotherapeutics Inc(SABS)?
The next earnings date of SAB Biotherapeutics Inc(SABS) is 2026-08-07 Est..
Does SAB Biotherapeutics Inc(SABS) pay dividends? If so, how much?
SAB Biotherapeutics Inc(SABS) does not pay dividend.
Guru Commentaries on NAS:SABS
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS | 2021-11-25 |
Articles on SAB Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers